Mammalian Cell Fermentation Technology Market Size & Share, by Type (Chinese Hamster Ovary [CHO] Cell Fermentation, Human Embryonic Kidney [HEK] Cell Fermentation, Baby Hamster Kidney [BHK] Cell Fermentation); Application (Monoclonal Antibodies, Recombinant Proteins, Vaccines, Others); End-Use (CMOs & CDMOs, Biopharmaceutical Companies) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2024-2036

  • Report ID: 5561
  • Published Date: Jan 23, 2024
  • Report Format: PDF, PPT

Top Featured Companies Dominating the Mammalian Cell Fermentation Technology Landscape

top-features-companies
    • Shanghai Henlius Biotech, Inc.
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Evonik
    • Thermo Fisher Scientific Inc.
    • General Electric
    • Danaher Corporation
    • Merck KGaA
    • Sartorius AG
    • Amgen, Inc.
    • Eppendorf AG
    • Pall Corporation

Browse Key Market Insights with Data Illustration:

In-the-news

In The News

  • Shanghai Henlius Biotech, Inc. stated that it has signed an exclusive licence deal with Fosun Pharma to commercialise the anti-PD-1 monoclonal antibody (mAb) HANSIZHUANG, which Henlius independently created, in the US. The conditions of the deal state that Henlius will continue to be in charge of development, manufacture, and supply, while Fosun Pharma will have the authority to commercialise HANSIZHUANG in the US following approval.
  • A highly pure cystine peptide is now available from Evonik to help with formulation issues with cell culture media and other methods that are utilized in the creation and manufacturing of biopharmaceuticals. Globally accessible, cQrex AC is a chemically defined, highly soluble source of L-cystine that allows cells to get enough of this essential amino acid. 

 


Author Credits:  Radhika Gupta, Shivam Bhutani


  • Report ID: 5561
  • Published Date: Jan 23, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

The major factors driving the growth of the market are growth in making of personalized medications, advancement in technology for mammalian cell fermentation, and rising chronic disease.

The market size of mammalian cell fermentation technology is anticipated to attain a CAGR of 9% over the forecast period, i.e., 2024-2036.

The major players in the market are Shanghai Henlius Biotech, Inc., Evonik, Thermo Fisher Scientific Inc., General Electric, and others.

The Chinese hamster ovary (CHO) cell fermentation segment is anticipated to garner the largest market size by the end of 2036 and display significant growth opportunities.

The market in the North America region is projected to hold the largest market share by the end of 2036 and provide more business opportunities in the future.
Inquiry Before Buying Request Free Sample
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying